Getting Started with the Vue Signature Pad Component

Arun - Nov 10 '22 - - Dev Community

Learn how easily you can create and configure Vue Signature component of Syncfusion using the Vue CLI command. This video also explains how to configure a few of the control’s basic features like changing the background color, stroke color, velocity, minimum and maximum stroke width, and applying a background image. You can also learn how to save a signature as an image and clear the image.

Download an example from GitHub: https://github.com/SyncfusionExamples/getting-started-with-the-vue-signature-pad-component

Refer to the following documentation: https://ej2.syncfusion.com/vue/documentation/signature/getting-started/

Check out this online example: https://ej2.syncfusion.com/vue/demos/#/bootstrap5/signature/default.html

Image
A step toward lasting path: The result regarding globalization in China's carbon output via solar panel patience method.
Image
Consecutive multimodal photo of singled out necrotic full-thickness macular gap extra for you to toxoplasma retinochoroiditis.
Image
Human being Decision-Making being a Primary factor inside the Chance of Wolf-Dog Connections throughout Outside Pursuits.
Image
How Gen AI Aligns with Blue Ocean Strategy
Image
Treating the relationship from the nontarget stick and the outcome allows for subsequent human predictive understanding.
Image
Fresh dominant distal titinopathy phenotype associated with backup amount variation.
Image
Circumstance statement of your solitary fibrofolliculoma about the alar casing.
Image
Post-translational modifications speak along with crosstalk in order to course IIa histone deacetylases.
Image
Unlocking Relief: Your Guide to Medical Marijuana in Hattiesburg, MS
Image
The role associated with PD-1/PD-L1 gate throughout arsenic bronchi tumorigenesis.
Image
Interaction involving health and also amyotrophic lateral sclerosis: Specialized medical influence.
Image
A Analysis Sign SLC2A3 Fits Together with EMT along with Resistant Trademark throughout Intestinal tract Cancers.
Image
Peace with the Interface Opposition between Strong Electrolyte and also 5 V-Class Beneficial Electrode.
Image
Human being platelet lysate -- A potent (and also disregarded) orthobiologic.
Image
Most affordable Whisper API

whisper, openai, api, ai
Image
Why Christopher Hildebrant is a Name to Know in Cincinnati
Image
The growth of the Files Bad: The actual COVID-19 Pandemic Seen In the Margins.
Image
Well-designed Fc Gamma Receptor Gene Polymorphisms and Long-Term Elimination Allograft Success.
Image
Different environment drivers involving innate and phenotypic divergence within an Andean toxin frog (Epipedobates anthonyi).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .